**Results** Systematic structure-activity relationship (SAR) investigation identified novel EP2 and EP4 dual antagonists. The most promising compound KT-00113 possesses high potency against both EP2 and EP4, while maintaining high selectivity over other prostanoid receptors. In vitro and in vivo ADMET studies show that KT-00113 has a favorable profile, apt for further examination in in vivo cancer models and immune cell function in tumors.

**Conclusions** KT-00113, a highly potent and selective EP2/4 dual antagonist has strong potential to become the best-in-class immune suppression lifting cancer immunotherapy and may be suitable for further development in a clinical setting.

**REFERENCES**


http://dx.doi.org/10.1136/jitc-2020-SITC2020.0707

**APPLICATION OF A NOVEL MSSENS DRUG DELIVERY TECHNOLOGY FOR MRNA THERAPEUTICS**

Sojin Lee*, Joon Young Park, Goo-Young Kim, Sang Woo Jo, Minhyuk Yun, Hye Yeong Nam, Helen Cho, Samyang Biopharmaceuticals Corporation, Gyeonggi-do, Korea, Republic of

**Background** Successful clinical translation of mRNA therapeutics requires an appropriate delivery strategy to overcome instability of mRNA and facilitate cellular uptake into the cells. Several lipid based nanoparticle approaches that encapsulate mRNA, notably lipid nanoparticle (LNP), have been developed, but their efficiency for delivery to certain target tissues and toxicity profiles still have room for improvement. The application of a novel polymer based nanoparticle technology platform, so called Stability Enhanced Nano Shells (SENS) for mRNA (mSENS) as a mRNA delivery platform for a cancer vaccine was demonstrated.

**Methods** The physicochemical properties of mSENS formulation, particle size and encapsulation efficiency, were characterized using dynamic light scattering (DLS) and gel retardation assay. Using luciferase-encoding mRNA, the protein expression levels in vitro and in vivo were evaluated by luciferase assay or bioluminescence imaging (BLI), respectively. For cancer vaccine studies, antigen (tyrosinase-related protein 2 (Trp-2)) specific T cell responses were assessed by immunophenotyping mouse splenocytes using flow cytometry and by the enzyme-linked immunosorbent spot (ELISPOT). T cell responses were not observed in Trp-2-mSens treated mice was evaluated through flow cytometry and complete blood count (CBC) tests.

**Results** A library of mSENS formulations complexed with luciferase-encoding mRNA, were characterized for their particle size, surface charge, encapsulation efficiency, colloidal stability, and in vitro and in vivo luciferase protein expression level. Upon systemic administration in mice, varying biodistribution profiles were observed, implicating the potential for tailored delivery to target tissues. Particularly, cancer vaccine application was further developed leveraging the formulation with preferential spleen delivery. Following vaccination with Trp-2 mRNA encapsulated with mSENS (Trp-2 mRNA-mSENS) in B16F10 tumor bearing mice, strong Trp-2 antigen-specific IFN-γ T-cell responses were observed. Generated anti-tumor immunity also marked suppression of B16F10 lung tumors were observed in Trp-2-mSens immunized mice compared to non-immunized controls, demonstrating the potential of mSens as a mRNA delivery platform for the application for vaccine.

**Conclusions** Proprietary biodegradable polymer based-mSens platform offers an attractive delivery strategy for mRNA by tailoring to specific therapeutic applications. Depending on the application, whether it’s a vaccine or protein replacement, a rationally designed mSens formulation can efficiently distribute mRNA to specific tissues. In particular, application of a splenic mSens formulation for a cancer vaccine has been demonstrated in murine tumor model. In summary, mRNA delivery through mSens platform is expected to provide significant opportunities in clinical development for mRNA therapeutics.

**Ethics Approval** The study was approved by Samyang Biopharmaceuticals’ IACUC (Institutional Animal Care and Use Committee), approval number SYAU-2027.

http://dx.doi.org/10.1136/jitc-2020-SITC2020.0708

**EXOSOME SURFACE DISPLAY OF IL-12 RESULTS IN TUMOR-RETAINED PHARMACOLOGY WITH SUPERIOR POTENCY AND LIMITED SYSTEMIC EXPOSURE**

Nuruddeen Lewis*, Chang Ling Sia, Katherine Kirwin, Sonya Haupt, Gauri Mahimkar, Tong ZJ, Ke Xu, Kevin Dooley, Su Chul Jang, Bryan Choi, Andrew Grube, Christine McCoy, Jorge Sanchez-Salazar, Michael Doheity, Scott Estes, Kyriakos Economides, Douglas Williams, Sriram Sathyamanyanan. Codiak BiSciences, Andover, MA, USA

**Background** The promise of Interleukin-12 as a cancer treatment has yet to be fulfilled with multiple tested approaches being limited by unwanted systemic exposure and unpredictable pharmacology. To address these limitations, we generated exoIL-12™, a novel, engineered-exosome therapeutic that displays functional IL-12 on the surface of an exosome.

**Methods** IL-12 exosomal surface expression was achieved via fusion to the abundant exosomal surface protein PTGFRN. Potency was assessed in vitro using human PBMCs or murine splenocytes and in vivo using mouse subcutaneous tumor models. Local versus systemic pharmacology was determined with intratumoral injection in mice and subcutaneous injection in monkeys. All studies were benchmarked against recombinant IL-12 (rIL-12).

**Results** Exosomes engineered to express either murine or human IL-12 had equivalent potency in vitro to rIL-12 as...
DEVELOPMENT OF IL-33 AS A NOVEL IMMUNOTHERAPY OF CANCER

1Joshua Zhonga, 2Runsi Sunb, 2Binfeng LuC. Carlmont High School, Belmont, CA, USA; 2University of Pittsburgh, Pittsburgh, PA, USA

Background Immune-checkpoint-blockade (ICB) therapy has produced unprecedented survival benefits for cancer patients but such therapy has been limited by low response rates in most cancer. One major obstacle for ICB therapy is the reduced immunogenicity of tumor tissues due to genetically driven down-regulation of epithelial tissue cytokines. IL-33 is a member of the IL-1 gene family and its level is downregulated in many advanced carcinomas such as lung cancer, breast cancer and pancreatic cancer. It has recently been shown that IL-33 plays an important role in mediating cancer immune therapy. In addition, transgenic expression of the active form of IL-33 in tumor cells or administration of the recombinant IL-33 exerts strong antitumor effects. Mechanistically, IL-33 enhances the function of Th1 and CD8+ T cells in vitro and types 1 antitumor immune responses in vivo.

Methods In the current study, we have optimized the pharmacodynamics of IL-33 by engineering a fusion protein, called anti-HSA-IL-33, using IL-33 and an anti-human albumin antibody. We have used preclinical mouse tumor models to determine the efficacy and toxicity of this new molecule.

Results We have shown that anti-HSA-IL-33 has excellent antitumor activities alone and enhances the antitumor function of PD-1 mAbs. Despite causing increased inflammation, anti-HSA-IL-33 is well tolerated with limited toxicity in mice.

Conclusions These studies support further development of IL-33 as a novel cancer immunotherapy.

Ethics Approval The animal experiments have been approved by IACUC of University of Pittsburgh.

http://dx.doi.org/10.1136/jitc-2020-SITC2020.0709